All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen
January 26, 2024 – Company announcement no. 1
Please see attachment.
Contact information
Investor Relations
Disa Tuominen
+45 6038 5826
dkditu@chr-hansen.com
Press Relations
Sanne Seyer-Hansen
+45 6038 6207
dksash@chr-hansen.com
Attachment
